News & Articles

Impel's Co-founder and CSO, Dr. John Hoekman, will be on a panel discussion on Novel Approaches to Alzheimer’s Disease from 10:00 to 10:30 am on Wednesday, October 11 at the Neuro Advance conference in Boston. For more information, visit https://bbbiotechconference.com/conference-agenda.php?id=62...

New CEO will lead Impel’s unique CNS pipeline to the clinic and potential commercialization Seattle, WA—October 03, 2017—Impel NeuroPharma, Inc., a Seattle based biotechnology company, announced the appointment of veteran biotech executive Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Impel is developing first-in-class intranasal drug...

At the beginning of September, Impel NeuroPharma moved its headquarters to 201 Elliot, a new biotech lab and office building. “The office gives us capacity to grow, it takes us from startup mode to small company mode.” Dr. John Hoekman, Impel's CEO is quoted as saying in an article from the...

On Thursday, June 1 at 10:00 am, John Hoekman will be presenting at the 12th annual Neurotech Investing and Partnering Conference focused on drugs, devices, and diagnostics for the brain and nervous system. He will be giving a presentation in the session focused on “Parkinson's and Movement disorders." Now in its 12th...

The U.S. Patent and Trademark Office (USPTO) has issued to Impel NeuroPharma, Inc. a patent relating to the company's POD™ device. Patent number 9,550,036, entitled "NASAL DRUG DELIVERY DEVICE," is directed to a device for delivery of compounds to the nasal cavity and methods of using the same.   Impel is...

March 03, 2017 05:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as Independent Director of the Board of Directors. Mr. Nelson has over 20 years of experience with drug delivery, medical devices and drug...

SEATTLE, Feb. 7, 2017 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC. Camargo will be providing end-to-end regulatory consulting and strategic development services for Impel's pipeline of drug-device combination...